Stockscreener 앱 받기
2.19
9.50%
0.19
시장 영업 전:
2.17
-0.02
-0.91%
Nervgen Pharma Corp 주식(NGEN)의 최신 뉴스
NervGen rises as TD Cowen issues new BUY on lead asset - MSN
NervGen Pharma Corp. Financial Disclosures & SEC Filings - TradingView
NervGen Pharma (NGEN) Investor Relations, Earnings Summary & Outlook - Quartr
NervGen Pharma (NGEN) Receives Buy Rating from TD Cowen, Shares Rally - GuruFocus
NervGen stock rises as TD Cowen issues new Buy (NGEN:NASDAQ) - Seeking Alpha
NervGen stock initiated at Buy by TD Cowen ahead of phase 3 trial - Investing.com UK
ORIC Pharmaceuticals Positions for Growth in Expanding Oncology Market - Streetwise Reports
NGENNervGen Pharma Corp. stock news, filings & ratings - Quantisnow
California Pharma Co. Tests Breakthrough Cancer Drug, Cuts Death Risk 60% - Streetwise Reports
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
NervGen Pharma Raises US$60 Million in Underwritten Offering to Fund NVG-291 Program - TipRanks
United StatesMintz Advises On NervGen Pharma’s $60 Million Public Offering - Mondaq
US Biotech Co. Targets Muscular Dystrophy with First-In-Class Drug - Streetwise Reports
Nervgen’s CONNECT Trial Termination: What It Means for NGEN Investors - TipRanks
Biopharma Company Reveals High-Impact SCI Recovery Gains - Streetwise Reports
NGEN Stock Price and Chart — NASDAQ:NGEN - TradingView
NervGen Pharma Company Profile & Introduction - Moomoo
These stocks have an unusual volume in today's session - ChartMill
NervGen reports positive gait analysis data for NVG-291 trial - grafa.com
NervGen Pharma (NGEN) Reports Promising Gait Analysis Results - GuruFocus
Why Is NervGen Pharma Stock Gaining Tuesday? - Benzinga
NervGen reports positive gait analysis data for NVG-291 trial By Investing.com - Investing.com Australia
NervGen Pharma Corp. Announces Positive Independent Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery With NVG-291 In Phase 1b/2a CONNECT SCI Study - marketscreener.com
NervGen Pharma Reports Positive Biomechanical Gait Analysis Results for NVG-291 Demonstrating Genuine Neural Recovery in Chronic Tetraplegia - Quiver Quantitative
Spinal cord injury trial: NervGen drug improves walking control - Stock Titan
Assessing NervGen Pharma (NasdaqCM:NGEN) Valuation After Its $60 Million Follow On Equity Offering - Sahm
NervGen Pharma Raises Capital to Advance Therapy for Spinal Cord Injury - techcouver.com
NervGen launches underwritten public offering of shares and warrants - MSN
NGEN Slides As NervGen Pharma Dilution Hits Share Price - timothysykes.com
NervGen Pharma prices 24M share public offering; warrants exercisable at $3.68 - MSN
NervGen Pharma Prices $60 Million Share Offering - Moomoo
HC Wainwright & Co. initiates coverage of NervGen Pharma (NGEN) with buy recommendation - MSN
NGEN: Joint Book Runners for Recent Offering Announced - GuruFocus
NervGen Pharma Shares Continue Sliding on Size of $60 Million Share Sale - Moomoo
Keep an eye on the top gainers and losers in Friday's session. - ChartMill
Biggest stock movers Friday: Quantum computing stocks, WDAY, ZM, and more - Seeking Alpha
NervGen Pharma stock tumbles on dilutive share offering By Investing.com - Investing.com India
NervGen Pharma, Medline, sociétés minières d'argent - TradingView
NervGen Pharma stock tumbles on dilutive share offering - Investing.com
2.60%
0.94%
자본화:
|
볼륨(24시간):